‘ALL’ about metabolism: repurposing drugs for acute lymphoblastic leukaemia
Examining whether a group of drugs called gliflozins could be used to treat T-ALL
Developing innovative new treatments for difficult to treat types of medulloblastoma
Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.
Understanding the evolution of neuroblastoma to improve treatment
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
Improving treatment decisions and outcomes in low grade glioma
Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma
Using next-generation gene technology to help children with blood cancers in low-income countries.
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
Developing personalised treatments for brain-directed chemotherapy in childhood acute lymphoblastic leukaemia
ALLTogether1 CSF-FLOW Study
Enhancing immunotherapy for the treatment of paediatric brain tumours
Enhancing CAR T-cell expansion and prolonged persistence for the effective treatment of paediatric medulloblastoma
A molecular approach to predict recurrence or spread of cancer that will lead to improving outcomes for children with rhabdomyosarcoma
MG-fnRMS and CINSARC gene expression signatures to predict relapse in fusion gene negative rhabdomyosarcomas: assessing an approach to improve patient outcomes
Identifying the genetic changes in T-cell acute lymphoblastic leukaemia that fails to respond to chemotherapy
Deciphering the genomic landscape of childhood refractory t-cell acute lymphoblastic leukaemia